Iambic’s $150 Million IPO Puts AI Drug Discovery in Wall Street’s Spotlight -( $IAM $IBB $JNJ $LLY $NVDA $TAK $XBI )

Nvidia-backed biotech pairs a clinical-stage cancer pipeline with pharmaceutical partnerships as TRex Bio, Retension and Lycia join the IPO queue

October 8, 2026

Artificial intelligence has spent the past several years promising to transform drug discovery. Iambic Therapeutics is now asking Wall Street to help finance the next, considerably more consequential chapter: testing those ambitions in patients. The San Diego company, backed by Nvidia (NASDAQ: NVDA), plans to offer approximately 9.38 million shares at $15 to $17 each and list on Nasdaq under the proposed ticker IAM. At the $16 midpoint, the offering would raise approximately $150 million gross, translating into about $135 million after expenses. Reuters reports that the upper end of the proposed range would value the company at approximately $805.8 million, based on the outstanding shares cited in its filing. The offering remains proposed, not completed. For many, the attraction is not simply another application of AI. It is the combination of a clinical-stage oncology pipeline, an established cash position and pharmaceutical collaborations that give Iambic several ways to build value. The algorithms may open the door, but the medicines will have to earn their seats at the table.

Iambic’s IPO Offers More Than an AI Label

Iambic enters its proposed public-market debut with $207.9 million in cash and cash equivalents at the end of June. Assuming the offering proceeds as planned, the company expects its existing resources and anticipated IPO proceeds to support operations through the end of 2028. That funding horizon is central to the bullish case. It would give Iambic time to advance its lead cancer therapy, bring additional candidates into human studies and continue developing its AI platform. Rather than financing a single experiment, the proposed offering supports a broader development agenda. The planned allocation of proceeds makes that agenda unusually concrete:

• $75 million for IAM1363, its lead HER2 inhibitor, including ongoing Phase 1 development and plans to initiate Phase 2 and Phase 3 studies.
• $15 million to bring IAM217, a KIF18A inhibitor, into the clinic.
• $15 million to initiate a Phase 1 study of IAM-C1, a dual CDK2 and CDK4 inhibitor.
• $20 million for the company’s AI platform, including new versions of Enchant and NeuralPLexer.

The proposition is therefore more specific than “AI will change healthcare.” Iambic is proposing to spend capital on identifiable drug candidates and the technology that helps generate them.

IAM1363 Gives the Technology Story a Clinical Center of Gravity

Iambic’s lead candidate, IAM1363, is an oral, brain-penetrant small-molecule HER2 inhibitor undergoing a Phase 1 study in patients with advanced HER2-altered solid tumors. The company intends to use a substantial portion of its IPO proceeds to support its further development. Its brain-penetrant design is an important feature of the intended product profile, but it should not be confused with established clinical benefit. IAM1363 remains an investigational medicine, and the current investment thesis depends on what subsequent studies demonstrate, not merely what the molecule was designed to do. Behind it, Iambic is building a pipeline with distinct biological targets:

• IAM217 is a brain-penetrant allosteric KIF18A inhibitor being developed for ovarian cancer, triple-negative breast cancer and other solid tumors.
• IAM-C1 is a selective dual CDK2 and CDK4 inhibitor aimed at breast cancer and CCNE1-amplified cancers.

For bullish investors, that breadth offers the possibility of multiple development opportunities rather than reliance on one program. It does not eliminate clinical risk, but it makes Iambic’s story more substantial than a platform demonstration with a stock-market prospectus attached.

Takeda’s Collaboration Adds Commercial Weight

A particularly important piece of Iambic’s investment narrative is its multiyear collaboration with Takeda Pharmaceutical (NYSE: TAK).Announced in February, the agreement gives Takeda access to Iambic’s AI drug-discovery technologies and laboratory capabilities, initially for programs in oncology, gastrointestinal diseases and inflammation. It also includes access to NeuralPLexer, Iambic’s model for predicting how proteins and drug molecules interactThe financial structure includes upfront payments, research funding and technology-access payments. Iambic could also receive success-based payments exceeding $1.7 billion, along with royalties on products generated through the collaboration.The distinction matters: that potential milestone total is not cash already received, guaranteed revenue or an amount investors should simply add to Iambic’s valuation. It is contingent upside tied to future achievements.Still, the agreement provides a tangible commercial relationship alongside the company’s internal pipeline. Takeda is accessing both software and discovery capabilities, which gives the partnership broader significance than a narrowly defined technology trial. Iambic also counts Nvidia (NASDAQ: NVDA) and AbbVie (NYSE: ABBV) among its backers, while Fierce Biotech reports that AbbVie joined its roster of collaborators in September. Those relationships strengthen the company’s industry credentials, although they do not substitute for favorable clinical results.

The AI Platform Connects Prediction With Experiment

Iambic’s platform combines computational models with automated laboratory work. NeuralPLexer predicts protein and protein-ligand structures, while Enchant is designed to predict clinical and preclinical endpoints. The company says these technologies operate alongside chemical synthesis and experimental testing in a recurring design, make, test and analyze process. That integration is the central technological proposition. A model can suggest a promising molecule, but laboratory experiments must establish whether its predictions hold up. Iambic says its integrated platform completes design-and-testing cycles on a weekly cadence.The potential appeal lies in improving how candidates are selected and refined before they advance. Whether that translates into better clinical outcomes remains a question for the trials. Biology, after all, has never been particularly impressed by a polished slide deck.

Other Biotech IPO Filings Expand the Watchlist

Iambic is not approaching the public markets alone. TRex Bio, Retension Pharmaceuticals and Lycia Therapeutics have also disclosed IPO plans, offering investors exposure to different therapeutic areas and development strategies. Their symbols below are proposed listing tickers, not confirmation that trading has begun.

TRex Bio: An Immunology Offering With Pharmaceutical Ties

TRex Bio plans to list under the proposed Nasdaq ticker TRXB. Its proposed offering consists of approximately 8.3 million shares at $14 to $16 each. At the midpoint, the company expects approximately $111.3 million in net proceeds, potentially increasing to $128.7 million if the underwriters fully exercise their additional-share option. The company develops therapies intended to modulate regulatory T cells, which help govern tissue inflammation. Its lead candidate, TRB-061, is a TNFR2 agonist being developed for atopic dermatitis and other autoimmune and inflammatory conditions. TRex expects to allocate $90 million to Phase 2 development and additional indications, with topline results from its ongoing Phase 1 atopic dermatitis study expected in mid-2027. TRex also has relationships with Eli Lilly (NYSE: LLY) and Johnson & Johnson (NYSE: JNJ). Lilly has expressed interest in participating in the IPO, although that indication of interest should not be treated as a completed purchase. The bullish angle is straightforward: an immunology-focused platform, a defined clinical program and established pharmaceutical relationships. The next important proof point is clinical data.

Retension Pharmaceuticals: A Focused Hypertension Proposition

Retension Pharmaceuticals has applied to list on the Nasdaq Capital Market under the proposed ticker RTSN. It plans to offer 3.3 million shares at $11 to $13 each, targeting approximately $33.8 million in net proceeds at the midpoint.Its lead candidate, RTN-001, is a once-daily oral PDE-5 inhibitor being developed for uncontrolled hypertension. Retension plans to allocate $18 million to complete a Phase 2b study and a further $10 million toward a Phase 3 study. The company says RTN-001 has been engineered for increased bioavailability and distribution to muscular arteries. It also reports clinically meaningful reductions in systolic and diastolic blood pressure in pilot Phase 2 studies. Those findings are encouraging company-reported signals, not a replacement for confirmation in larger trials. Compared with Iambic’s platform-and-pipeline proposition, Retension presents a more concentrated investment thesis: whether one lead therapy can demonstrate a differentiated benefit in hypertension.

Lycia Therapeutics: Protein Degradation Moves Toward Nasdaq

Lycia Therapeutics filed for an IPO on October 5 and has applied to list on the Nasdaq Global Market under the proposed ticker LYCA. Its preliminary filing leaves the offering’s share count and price range blank, so final deal terms remain unspecified. Renaissance Capital describes the initial fundraising target as up to $100 million. Lycia’s lead candidate, LCA-0061, is a catalytic lysosomal targeting chimera, or cataLYTAC, designed to deplete immunoglobulin E, known as IgE, for food allergy and other allergic diseases. The candidate is undergoing a Phase 1 trial. Additional programs include LCA-0062 for food allergy and LCA-0321 for Graves’ disease. The company entered the second half of 2026 with $148.1 million in cash, according to Fierce Biotech. Its potential appeal rests on advancing a differentiated protein-degradation approach into clinical evidence, with an existing cash position supporting that effort.

What Many Should Watch Next

For Iambic, execution is the bridge between an attractive financing story and a durable investment case. The proposed IPO would support three connected priorities: advancing IAM1363, bringing additional oncology candidates into human studies and improving the discovery platform. Pharmaceutical collaborations add another potential source of value, but the internal pipeline remains a major focus of the planned spending. The most useful checkpoints are:

• Final offering terms and completion. Iambic’s price range and fundraising figures remain proposed.
• Clinical progress for IAM1363. The lead program is currently in Phase 1, with later-stage development included in the planned use of proceeds.
• Entry of additional candidates into the clinic. IAM217 and IAM-C1 would broaden the company’s human-development portfolio if their planned studies begin.
• Partnership achievements. Takeda’s largest potential payments depend on future success, making actual milestones more informative than the headline agreement value alone.

The risks deserve equal clarity. These are investigational therapies, proposed offerings can change, and a funding horizon through 2028 is not the same as financing every program through approval. Iambic’s appeal is the opportunity to convert a well-funded platform and several drug-development efforts into meaningful clinical progress, not a guarantee that it will do so. For many seeking exposure to AI-enabled drug discovery, Iambic offers an unusually tangible proposition: technology, clinical assets and commercial partnerships in one proposed listing. The bullish case begins with that combination. Its staying power will be determined in the clinic.

The Sources

1. Fierce Biotech: AI biotech Iambic aims for $135M IPO to push cancer drugs through clinic
   October 8, 2026. Covers Iambic’s expected net proceeds, oncology pipeline, planned spending and cash runway.
2. Reuters: Nvidia-backed Iambic Therapeutics targets up to $806 million valuation in US IPO
   October 8, 2026. Reuters reporting, republished by KELO, detailing the proposed offering size, price range and valuation.
3. Iambic Therapeutics: Collaboration With Takeda to Advance AI-Driven Design of Small Molecules
   February 9, 2026. Company announcement describing the collaboration, AI technologies, payment structure and potential success-based payments.
4. Reuters: Takeda deepens AI drug discovery push with $1.7 billion Iambic deal
   February 9, 2026. Independent reporting on the Takeda collaboration and its therapeutic focus.
5. Fierce Biotech: TRex Bio stomps toward $111M IPO, as Retension and Lycia also gear up to go public
   October 6, 2026. Covers the three companies’ IPO plans, clinical programs and intended uses of proceeds.
6. MarketWatch: Retension Pharmaceuticals to sell 3.3 million shares at $11–$13 each in IPO
   October 5, 2026. Reports Retension’s proposed offering terms and Nasdaq listing application.
7. Renaissance Capital: Lycia Therapeutics files for a $100 million IPO, targeting food allergies
   October 5, 2026. Summarizes Lycia’s filing, initial fundraising target and clinical-stage pipeline.
8. U.S. Securities and Exchange Commission: Lycia Therapeutics registration filing
   Primary filing supporting Lycia’s proposed listing and preliminary offering disclosures.